http://xeloda.legalview.com/msn/ 2012-02-23 http://xeloda.legalview.com/msn/battling-jo-vows-to-fulfil-a-dream/1234952/ 2012-02-23 http://xeloda.legalview.com/msn/genentech-gets-refuse-to-file-letter-for-t-dm1-bla/1234951/ 2012-02-23 http://xeloda.legalview.com/msn/genentech-updates-status-of-fda-application-for-t-dm1/1234950/ 2012-02-23 http://xeloda.legalview.com/msn/fda-kicks-breast-cancer-drug-back-to-genentech/1234949/ 2012-02-23 http://xeloda.legalview.com/msn/ways-in-which-fingerprints-can-fade/1234948/ 2012-02-23 http://xeloda.legalview.com/msn/today-in-the-press/1234947/ 2012-02-23 http://xeloda.legalview.com/msn/new-cancer-drugs-funded/1234946/ 2012-02-23 http://xeloda.legalview.com/msn/a-look-at-immunogen-beyond-the-t-dm1-setback/1234945/ 2012-02-23 http://xeloda.legalview.com/msn/adjuvant-chemo-drugs-equal-for-pancreatic-cancer/1234944/ 2012-02-23 http://xeloda.legalview.com/msn/aeterna-zentaris-aezs-reports-final-results-of-phase-2-study-of-perifo/1196699/ 2012-02-23 http://xeloda.legalview.com/msn/aeterna-zentaris-keryx-says-cancer-drug-perifosine-meets-phase-2-trial/1196698/ 2012-02-23 http://xeloda.legalview.com/msn/nektars-drug-holds-strong-potential/1196697/ 2012-02-23 http://xeloda.legalview.com/msn/aeterna-zentaris-aezs-reports-final-results-of-phase-2-study-on-perifo/1196696/ 2012-02-23 http://xeloda.legalview.com/msn/thousands-of-breast-cancer-patients-to-be-denied-life-prolonging-drug/1196695/ 2012-02-23 http://xeloda.legalview.com/msn/nice-rules-against-nhs-funding-for-tyverb-lapatinib-an-effective-treat/1196694/ 2012-02-23 http://xeloda.legalview.com/msn/glaxo-cancer-drug-rejected-for-uk-state-funding/1196693/ 2012-02-23 http://xeloda.legalview.com/msn/keryx-announces-final-results-of-mid-stage-study-of-colorectal-cancer/1196692/ 2012-02-23 http://xeloda.legalview.com/msn/nice-rejects-breast-cancer-drug/1196691/ 2012-02-23 http://xeloda.legalview.com/msn/new-breakthroughs-in-cancer-treatment/1196690/ 2012-02-23 http://xeloda.legalview.com/msn/keryx-presents-encouraging-data/1196689/ 2012-02-23 http://xeloda.legalview.com/msn/update-1-glaxo-cancer-drug-rejected-for-uk-state-funding/1196688/ 2012-02-23 http://xeloda.legalview.com/msn/breast-cancer-victims-to-be-denied-life-extending-drug/1196687/ 2012-02-23 http://xeloda.legalview.com/msn/keryx-biopharma-kerx-updates-on-krx-0401-in-combo-with-xeloda-phase-ii/1196686/ 2012-02-23 http://xeloda.legalview.com/msn/archive-for-may-2009/1158932/ 2012-02-23 http://xeloda.legalview.com/msn/intensive-rectal-cancer-treatment-shows-promise/1158931/ 2012-02-23 http://xeloda.legalview.com/msn/genta-initiates-confirmatory-phase-2b-trial-of/1158930/ 2012-02-23 http://xeloda.legalview.com/msn/swiss-stocks-advance-ubs-credit-suisse-roche-lead/1158929/ 2012-02-23 http://xeloda.legalview.com/msn/lilly-aims-to-sell-15-new-products-in-china-roches/1158928/ 2012-02-23 http://xeloda.legalview.com/msn/eu-approves-roches-xeloda-combined-with-oxaliplatin/1158927/ 2012-02-23 http://xeloda.legalview.com/msn/roches-xeloda-approved-for-colon-cancer-use-in-eu/1158926/ 2012-02-23 http://xeloda.legalview.com/msn/improved-recurrence-free-survival-with-capecitabine-but-increased/1131747/ 2012-02-23 http://xeloda.legalview.com/msn/ruben-rosario-health-care-for-prison-inmates-the-real-public-option/1131746/ 2012-02-23 http://xeloda.legalview.com/msn/report-highlights-cancer-advances/1131745/ 2012-02-23 http://xeloda.legalview.com/msn/gastric-cancer-drug-market-to-double-to-nearly-15-billion-in-2018/1131744/ 2012-02-23 http://xeloda.legalview.com/msn/hot-off-the-wire/1131743/ 2012-02-23 http://xeloda.legalview.com/msn/landmark-study-in-the-lancet-oncology-shows-capecitabine-xelodar/1131742/ 2012-02-23 http://xeloda.legalview.com/msn/pancreatic-cancer-advances-in-medical-therapy/1109072/ 2012-02-23 http://xeloda.legalview.com/msn/elderly-breast-cancer-patients-receive-chemotherapy-if-treated-in/1109071/ 2012-02-23 http://xeloda.legalview.com/msn/nice-upholds-glaxosmithkline-appeal-for-advanced-breast-cancer/1109070/ 2012-02-23 http://xeloda.legalview.com/msn/xeloda-in-combination-with-oxaliplatin-shown-to-be-effective-in-early/1109069/ 2012-02-23 http://xeloda.legalview.com/msn/nexavar-in-combination-with-chemotherapy-shown-to-extend-progression/1109068/ 2012-02-23 http://xeloda.legalview.com/msn/lorus-therapeutics-reports-results-for-fiscal-year-2009/1109067/ 2012-02-23 http://xeloda.legalview.com/msn/uks-nice-reconsiders-block-on-glaxo-cancer-drug/1109066/ 2012-02-23 http://xeloda.legalview.com/msn/new-strategy-in-tumor-treatment/1109065/ 2012-02-23 http://xeloda.legalview.com/msn/roches-xeloda-improves-disease-free-survival-after-colorectal/1109064/ 2012-02-23 http://xeloda.legalview.com/msn/update-2-bayer-says-nexavar-shows-promise-in-breast-cancer/1109063/ 2012-02-23 http://xeloda.legalview.com/msn/xeloda-in-combination-with-oxaliplatin-shown-to-be-effective-in-early/1109062/ 2012-02-23 http://xeloda.legalview.com/msn/array-biopharma-reports-financial-results-for-the-fourth-quarter-and/1109061/ 2012-02-23 http://xeloda.legalview.com/msn/adding-a-cancer-drug-may-make-matters-worse/1109060/ 2012-02-23